You're Eating Fish and Still Depleted. Here's the Genetic Reason.

FADS1 encodes delta-5 desaturase, the final enzyme in the chain that converts plant-based omega-3s (ALA) into EPA and then into the most active omega-3 form, DHA. Without this enzyme working properly, your body stops the conversion pipeline before it reaches the forms your brain actually needs.

The rs174537 variant in FADS1 is carried by roughly 30-40% of people, depending on ancestry. People with this variant have reduced delta-5 desaturase activity, meaning they convert ALA to EPA at a fraction of the normal rate. Even if you eat flaxseeds and chia seeds daily, your cells are missing the critical intermediate step.

You feel this as brain fog, poor focus, difficulty with learning and memory formation, and sometimes depression. Your skin stays dry. Your joints ache. Your mood feels flat. All of these are classic signs of EPA and DHA deficiency, but they’re happening in a body that’s eating omega-3 sources correctly. The problem is the conversion machinery, not the diet.

FADS2 encodes delta-6 desaturase, the very first enzyme that begins converting ALA into longer omega-3 chains. It’s the gateway. If this enzyme is slow or inefficient, nothing downstream happens, no matter how much omega-3 you consume. The entire conversion pipeline stalls at step one.

The rs1535 variant in FADS2 is carried by approximately 30-40% of the population. Individuals with this variant have impaired delta-6 desaturase activity, cutting their conversion efficiency by a significant percentage and effectively halting the progression from ALA to EPA. Your body receives the signal that omega-3 is present, but the enzyme that’s supposed to start processing it simply doesn’t have enough capacity.

This feels like chronic inflammation, poor exercise recovery, unexplained fatigue, and sometimes heart palpitations. Your muscles take longer to repair. Your immune system feels overactive. You might develop eczema or psoriasis. Joints stiffen. These are all symptoms of EPA and DHA deficiency, but supplements of ALA won’t fix them because your FADS2 variant prevents the first critical conversion step.

APOE isn’t directly an omega-3 gene, but it’s critical. It encodes the protein that transports omega-3s (and all lipids) through the bloodstream to your tissues, including the brain. Different APOE variants bind EPA and DHA with different affinities. Some versions hold onto omega-3s and deliver them efficiently. Other versions let them slip through your system underutilized.

Approximately 25% of people carry the APOE4 variant. APOE4 carriers have reduced efficiency in transporting and utilizing EPA and DHA, even when blood levels are adequate. You can have normal omega-3 levels on blood work and still be functionally deficient at the cellular level because your APOE variant isn’t delivering the omega-3s to the tissues that need them most.

APOE4 variants often feel this as cognitive decline that seems disproportionate to their age, increased risk of brain fog, and sometimes early signs of memory problems. Joint pain that doesn’t match inflammation markers. Mood changes that don’t respond to typical interventions. Cardiovascular issues despite good cholesterol numbers. Your tissues are starving for omega-3s even though you’re taking supplements.

MTHFR isn’t directly about omega-3 metabolism, but omega-3s don’t work without a functioning methylation cycle. MTHFR encodes the enzyme that converts folate into its active form (methylfolate), which is essential for the methylation reactions that make EPA and DHA functional inside your cells. When MTHFR is impaired, your whole cellular communication system slows down, including the mechanisms that help omega-3s exert their anti-inflammatory effects.

Approximately 40% of people of European ancestry carry the C677T variant in MTHFR. This variant reduces the enzyme’s activity by 35-40%, slowing your methylation cycle and limiting the cellular ability to properly utilize omega-3s even when they’re present. You can take the best fish oil in the world, but if your methylation cycle is stuck, the omega-3s can’t do their job.

You experience this as persistent brain fog that doesn’t improve with omega-3 supplementation alone, slower cognitive processing, difficulty with mood regulation, and sometimes joint pain and muscle stiffness. Your energy feels depleted even after rest. Infections seem to linger. You might notice that supplements that help other people do almost nothing for you. The omega-3s are there, but your cells can’t properly methylate and utilize them.

VDR encodes the vitamin D receptor, which is expressed in virtually every cell type. But VDR doesn’t just regulate vitamin D. It also modulates cellular responses to omega-3s and controls the genetic expression of genes involved in inflammation and immune function. When VDR function is impaired, your cells literally cannot respond to omega-3 signals, even when omega-3 levels are adequate.

Approximately 30-50% of the population carries variants in VDR (BsmI, FokI, or TaqI), depending on ancestry. VDR variants reduce the receptor’s sensitivity, meaning your cells require higher circulating omega-3 levels to trigger the same anti-inflammatory response that someone with wild-type VDR would achieve. Your body is essentially less responsive to the omega-3s you’re taking.

This shows up as persistent inflammation despite adequate omega-3 intake, slow recovery from exercise or injury, chronic joint pain, and sometimes autoimmune-like symptoms. You might notice that your skin stays inflamed (eczema, acne) or your immune system seems overactive (frequent infections, allergies). Your VDR variant is preventing your cells from hearing the anti-inflammatory signal that omega-3s are sending.

PPARG encodes a nuclear receptor that acts as a master switch for metabolic inflammation. When activated, PPARG reduces inflammatory signaling and improves insulin sensitivity. Omega-3s (particularly DHA) are natural PPARG activators. But if you carry certain PPARG variants, your receptor is less responsive to these signals, and the anti-inflammatory benefits of omega-3s are muted.

Approximately 25-30% of the population carries the Pro12Ala variant in PPARG. People with this variant have reduced PPARG activity, meaning their metabolic inflammation stays elevated and omega-3 supplementation produces smaller improvements in inflammatory markers. Your body is biochemically less able to switch off the inflammatory state, even when given the tools (omega-3s) to do so.

You feel this as persistent fatigue, joint and muscle pain that doesn’t respond proportionally to supplementation, and sometimes mild metabolic dysfunction (weight gain despite healthy eating, slow metabolism, mild insulin resistance). You might also notice that your mood is harder to regulate and that your recovery from stress is slower. Omega-3s help, but not as much as they should because your PPARG variant is limiting the metabolic switch they’re trying to flip.